Hit by FDA red flags, cited for misleading investors and battered by a thumbs-down from experts, it’s been one terrible week for Trevena
Trevena’s fall from grace — and into penny stock territory — gathered steam on Thursday evening as a slight majority of outside experts at the FDA turned …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
